Review Fortune |
UPDATE 1-FDA rejects Ocular's post-operative eye pain treatment
Reuters (Adds details, background and share move). July 25 Drug developer Ocular Therapeutix Inc said the U.S. Food and Drug Administration had denied approval for its treatment for post-operative eye pain. The company said the FDA raised concerns related to ... Ocular Therapeutix (OCUL) Receives CRL from FDA Related to NDA for DEXTENZA FDA rejects Ocular's Dextenza NDA for ocular pain; shares off 4% premarket FDA rejects Ocular Therapeutix' Dextenza post-operative pain indication |
from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNFxLOO5UdNC2i6K6bYgAlvWPMmgog&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779167457458&ei=KBqWV6ieN4ec3QHZmpKABQ&url=http://www.reuters.com/article/ocular-fda-idUSL4N1AB3SG
via IFTTT
No comments:
Post a Comment